The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Virus and Host
Volume 14 - 2024 |
doi: 10.3389/fcimb.2024.1392491
Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
Provisionally accepted- 1 Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
- 2 Hugobiotech Co. Ltd., Beijing, China
- 3 Hainan Affiliated Hospital of Hainan Medical University, haokou, China
- 4 Tianjin First Central Hospital, Tianjin, China
Objective: This retrospective cohort study aimed to assess the clinical features, treatment outcomes, and short-term prognosis in kidney transplant recipients (KTRs) with concurrent coronavirus disease 2019 (COVID-19) pneumonia.Methods: KTRs with COVID-19 pneumonia who were admitted to our hospital from December 28, 2022, to March 28, 2023 were included in the study. Their clinical symptoms, responses to antiviral medications, and short-term prognosis were analyzed.Results: A total of 64 KTRs with initial diagnosis of COVID-19 pneumonia were included in this study. The primary symptoms were fever, cough, and myalgia, with an incidence of 79.7%, 89.1%, and 46.9%, respectively. The administration of antiviral drugs (paxlovid or molnupiravir) within 1-5 days and for over 5 days demonstrated a statistically significant reduction in viral shedding time compared to the group without antiviral medication (P=0.002). Both the paxlovid and molnupiravir treatment groups exhibited a significantly shorter duration of viral shedding time in comparison to the group without antiviral drugs (P=0.002). After 6 months of recovery, there was no significantly negative impact on transplant kidney function (P=0.294).Fever, cough, and myalgia remain common initial symptoms of concurrent COVID-19 pneumonia in KTRs. Early use of antiviral drugs (paxlovid or molnupiravir) is associated with better therapeutic outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a limited impact on the short-term renal function of the KTRs with concurrent moderate or severe COVID-19 pneumonia.
Keywords: Kidney transplant, COVID-19 pneumonia, PAXLOVID, Molnupiravir, prognosis
Received: 10 May 2024; Accepted: 22 Jul 2024.
Copyright: © 2024 Xu, Xiu Chen, Yang, Chen, Zehua, Zehua, Chen, Wang, Jiang, Xu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiu Xiu Chen, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Xuying Yang, Hugobiotech Co. Ltd., Beijing, China
Song Chen, Hainan Affiliated Hospital of Hainan Medical University, haokou, China
Yuan Zehua, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Rentian Chen, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Jianli Wang, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Hongtao Jiang, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Jian Xu, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Yi Wang, Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.